Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polymer microneedle for inhibiting cell inflammatory factors to treat acute attack of gout and preparation method of polymer microneedle

A technology for acute attack of gout and inhibition of inflammation, applied in the directions of microneedling, chemical instruments and methods, needles, etc., can solve the problems of not being suitable for preventing attacks, limiting the effect of drugs, short biological half-life, etc., to reduce the phenomenon of poisoning, prolong the Release time, the effect of improving the absorption rate

Inactive Publication Date: 2021-02-26
深圳前海鹰岗生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, some patients only partially respond to this treatment, and often relapse within 1-6 weeks after discontinuation
In addition, Canakinumab has a short biological half-life and requires daily subcutaneous administration, so it is not suitable for prevention of seizures; Canakinumab has a short half-life in the systemic circulation, which greatly limits its maximum drug effect in target tissues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polymer microneedle for inhibiting cell inflammatory factors to treat acute attack of gout and preparation method of polymer microneedle
  • Polymer microneedle for inhibiting cell inflammatory factors to treat acute attack of gout and preparation method of polymer microneedle
  • Polymer microneedle for inhibiting cell inflammatory factors to treat acute attack of gout and preparation method of polymer microneedle

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0057] 1. Preparation of pharmaceutical preparations

[0058] The pharmaceutical preparation of this example contains 0.005-0.05 parts by weight of canakinumab, 0.05-0.15 parts by weight of sodium phosphate, 0.0025-0.025 parts by weight of mannitol and 0.005-0.025 parts by weight of sodium chloride. In this example, the drug preparation was made into nanoparticles in advance, and then used in subsequent tests. The specific preparation method is as follows:

[0059] Weigh 0.05g of canakinumab and disperse it in the sodium phosphate buffer solution of pH7.1-9.0, add a small amount of polylactic acid-glycolic acid copolymer solution, the amount of polylactic acid-glycolic acid copolymer is about the weight of canakinumab 20%-70%, using a spray dryer to make the first nano particles. The sodium phosphate buffer contains 0.15 g of sodium phosphate.

[0060] Take by weighing 0.025g of sodium chloride and 0.025g of mannitol and mix evenly, and add in the polylactic acid-glycolic ac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
heightaaaaaaaaaa
heightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a polymer microneedle for inhibiting an inflammatory reaction and treating an acute attack of gout and a preparation method of the polymer microneedle. A nano-material-coated pharmaceutical preparation containing an effective dose of canakinumab is embedded into a needle tip of the polymer microneedle. The pharmaceutical preparation is prepared from the following componentsin parts by weight: 0.005-0.05 part of canakinumab, 0.05-0.15 part of sodium phosphate, 0.0025-0.025 part of mannitol and 0.005-0.025 part of sodium chloride. A microneedle patch is directly adheredto an ill part and the microneedle is simple and convenient to use. A nano-material is used for coating and slow release, so that the medicine can fully play a role and has better fixed-point and targeted treatment effects and a higher medicine utilization rate. The polymer microneedle solves a problem that the canakinumab is difficult to effectively act on an ill part for a long time through a systemic circulation and also avoids problems caused by excessive use of the canakinumab in a systemic way.

Description

technical field [0001] The present application relates to the technical field of gout treatment, in particular to a polymer microneedle for treating acute attack of gout by inhibiting inflammatory response and a preparation method thereof. Background technique [0002] Gout is a common disease in the world. According to epidemiological statistics, the prevalence rate of hyperuricemia reported in Europe and the United States in the 1990s was 2%-24%, and the prevalence rate of hyperuricemia reported in the United States in 1993 was 10.1%. According to statistics in China in 2008, the overall prevalence rate of hyperuricemia was 13.2-21.04%. The total prevalence of gout around the world is between 0.13-15.3%, and the global annual incidence is between 0.20%-0.35%. The incidence of gout and hyperuricemia in European and American countries is significantly higher than that in other countries, and it is increasing year by year. Among them, the prevalence of gout patients in the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K39/395A61K47/02A61K47/22A61K47/26A61K47/34A61K47/38A61P19/02A61P19/06A61P29/00A61M37/00
CPCA61K9/0021A61K47/34A61K47/22A61K47/38A61K47/26A61K47/02A61P19/02A61P19/06A61P29/00C07K16/245A61M37/00A61K2039/505A61M2037/0053
Inventor 霍亮向雄根黎永祥沈芝萍
Owner 深圳前海鹰岗生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com